PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CG Oncology (CGON) reported that cretostimogene reduced recurrence risk by 68% in its Phase 3 PIVOT-006 bladder cancer trial. The study met its primary endpoint versus control in intermediate-risk and high-grade Ta ≤3 cm non-muscle invasive bladder cancer following complete tumor removal. The hazard ratio was 0.32 (95% confidence interval: 0.23–0.45; p<0.0001), with median follow-up of 17 months as of October 26, 2026. No Grade 3 or higher treatment-related adverse events or treatment-related discontinuations occurred.
The company anticipates a second biologics license application in Q2 2027. Based on FDA feedback, it plans to broaden its initial application in BCG-unresponsive disease to include high-grade papillary-only disease alongside carcinoma in situ, with or without papillary tumors, and expects completion before the end of March 2027. Manufacturing activities needed to support both filings are complete.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointPIVOT-006 met its primary endpoint with a 68% reduction in recurrence risk versus control.
- Moderate point. Forward-looking: it has not happened yet and may not happen.CG Oncology anticipates a second biologics license application in Q2 2027 for intermediate-risk and high-grade Ta disease.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Initial BCG-unresponsive application expansion is planned to add high-grade papillary-only disease, with completion expected before March 2027 ends.
- Minor pointSafety results included no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations.
- Minor pointManufacturing activities needed to support both regulatory filings are complete.
Negative
- None.
Details
Market move: CGON +36.83% vs previous close. Phase 3 clinical data
On Nov 16, the day this news came out, the latest delayed price for CGON is 36.83% above the previous close. Argus tracked a peak move of +36.8% during the session. Our momentum scanner has recorded 17 alerts for this stock so far that day. The latest delayed price is $101.80. Relative volume is exceptionally heavy at 39.5x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Recurrence risk reduction
- 68%
- Cretostimogene versus the control arm
- Hazard ratio
- 0.32
- 95% CI: 0.23–0.45
- P-value
- p<0.0001
- PIVOT-006 recurrence result
- Grade 3 or higher TRAEs
- None reported
- PIVOT-006; no treatment-related discontinuations
- Median follow-up
- 17 months
- As of October 26, 2026
- Second BLA submission
- Q2 2027
- Anticipated; supported by PIVOT-006 data
- Broadened initial BLA submission
- Before the end of March 2027
- Completion anticipated after adding high-grade papillary-only disease
Previous Clinical trial Reports
-
Topline timing moved to 1H 2026 after expedited enrollment in the same PIVOT-006 trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
hazard ratio technical
nmibc medical
intravesical medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Cretostimogene reduced the risk of recurrence by
– Compelling safety and tolerability results, no Grade 3 or higher TRAEs and no treatment-related discontinuations
– PIVOT-006 topline results to be presented as a late-breaking podium presentation at the Society of Urologic Oncology Annual Meeting on December 2, 2026
– PIVOT-006 data will support a second BLA submission in intermediate-risk and high-grade Ta NMIBC anticipated in Q2 2027
– Based on FDA feedback, initial BLA submission in BCG-unresponsive NMIBC to be broadened to include both CIS and high-grade papillary-only disease; completion anticipated in March 2027
DALLAS, Nov. 16, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced positive topline results from PIVOT-006, its Phase 3 registrational trial evaluating adjuvant intravesical cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC, following complete tumor resection. There are currently no U.S. FDA approved adjuvant treatment options in this population of approximately 50,000 patients. Together with the Company’s data in high-risk BCG-unresponsive NMIBC, the PIVOT-006 results have the potential to significantly broaden the patient populations that could benefit from cretostimogene if approved.
PIVOT-006 achieved its primary endpoint, demonstrating statistically significant and clinically meaningful improvements versus the control arm. Cretostimogene resulted in a
“The unparalleled PIVOT-006 results represent a defining milestone for CG Oncology and position cretostimogene as the first and only therapeutic candidate to demonstrate a significant recurrence benefit in a pivotal Phase 3 trial in intermediate-risk and HG Ta NMIBC. We are working expeditiously to complete our BLA filing in intermediate-risk and HG Ta NMIBC in the second quarter of 2027,” said Arthur Kuan, Chairman, President and Chief Executive Officer of CG Oncology. “Based on FDA feedback, we plan to broaden our initial BLA submission in BCG-unresponsive NMIBC, which was focused on patients with CIS with or without papillary tumors, to also include patients with high-grade papillary-only disease. Together, these populations represent the full range of BCG-unresponsive patients, and our goal is a label that reflects that. To incorporate the additional data, we now expect to complete the submission before the end of March 2027. All BLA-enabling manufacturing activities supporting both regulatory filings have been completed. Ultimately, this strategy reflects our commitment to meaningfully improve the lives of as many bladder cancer patients as possible.”
“Today’s results highlight our differentiated clinical approach, aimed at exploring cretostimogene across the broad NMIBC spectrum and build upon our robust body of clinical evidence including what we believe to be the best-in-disease safety and tolerability data reported,” said Vijay Kasturi, M.D., Chief Medical Officer of CG Oncology. “For patients with intermediate-risk and high-grade Ta NMIBC, reducing recurrence is a meaningful clinical objective because recurrence can bring additional invasive procedures and continued disease burden. The significant improvement in recurrence-free survival observed in PIVOT-006 across both high-grade and low-grade patients underscores the promise of cretostimogene as an important potential new treatment option following tumor resection. These data give us the opportunity to change clinical practice and help more people remain cancer-free longer while reducing the burden of their disease.”
About PIVOT-006 Phase 3 Clinical Trial
PIVOT-006 is one of the largest randomized Phase 3 studies conducted in intermediate-risk NMIBC, and enrolled 367 patients across ~90 sites in the United States and Canada. Enrolled patients had the broadest range of disease characteristics specified in AUA/SUO guidelines at the time of study start including recurrent low-grade (LG) Ta < 12mo, solitary LG Ta > 3cm, LG Ta multifocal, solitary HG Ta ≤ 3cm and LG T1. The study compares adjuvant intravesical cretostimogene grenadenorepvec versus surveillance following complete tumor resection, reflecting real-world clinical practice in this patient population.
About Cretostimogene Grenadenorepvec
Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 700 patients with Non-Muscle Invasive Bladder Cancer (NMIBC). This program includes two Phase 3 clinical trials: BOND-003 for BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk and high-grade Ta ≤ 3cm NMIBC. Cretostimogene has received FDA Fast Track and Breakthrough Therapy designations for BCG-unresponsive NMIBC. CG Oncology also has a multi-cohort trial, CORE-008, evaluating the safety and efficacy of cretostimogene in BCG-exposed high-risk, BCG-naïve high-risk, and BCG-unresponsive NMIBC. Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet certain program eligibility requirements. Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Forward-Looking Statements
CG Oncology cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, the significant improvement in recurrence-free survival observed in the PIVOT-006 registrational trial, the potential therapeutic benefits of cretostimogene for high-risk and intermediate-risk NMIBC patients, the planned timelines of our BLA submissions and their respective indications, our goal of securing the broadest possible label and including the totality of the BCG-unresponsive population at launch, cretostimogene’s potential as a backbone immunotherapy across the NMIBC spectrum, the potential of PIVOT-006 results to change clinical practice and broaden the patient populations that could benefit from cretostimogene, and the expected patient population size that could benefit from cretostimogene, if approved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: topline data is based on preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial, and the FDA may not agree with our interpretation of such results; potential delays in the commencement, enrollment and completion of clinical trials; potential delays in the preparation, submission, acceptance, completion or review of our current and planned BLAs; the risk that regulatory authorities may require additional data or studies, may not approve cretostimogene, or may grant a narrower indication or label than anticipated; uncertainties regarding the timing and scope of any commercial launch and our ability to achieve anticipated patient access, market acceptance and therapeutic benefits; the risk that the target patient population size may be smaller than initially anticipated; we may use our capital resources sooner than expected and they may be insufficient to allow us to achieve our anticipated milestones; our dependence on third parties in connection with manufacturing, shipping and clinical and preclinical testing; results from earlier clinical trials and preclinical studies not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval, and/or commercialization; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our most recent annual report on Form 10-K and other filings that we make with the SEC from time to time. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com
Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.